L&C BIO Co., Ltd
L&C BIO manufactures human tissue grafts across 11 tissue types, including the acellular dermal matrix MegaDerm, plus tissue-based medical devices.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2011, L&C BIO listed on KOSDAQ in 2018 as a company specializing in human tissue grafts and tissue-based medical devices. It produces human tissue grafts across 11 tissue types—bone, cartilage, fascia, skin, amniotic membrane, ligament, tendon, heart valve, blood vessel, nerve, and pericardium—under MFDS approval; its flagship product, the acellular dermal matrix (ADM) MegaDerm, is used for breast reconstruction after cancer treatment, and it also manufactures and exports tissue-based medical devices such as MegaDBM S, MegaCure, MegaShield, and MegaCarti. It is developing a broad follow-on pipeline including MegaNerve Prime (peripheral nerve replacement, co-developed with Czech firm PrimeCell), MegaFill Putty and TendonFill (pending process validation), and Mega3DEar, MegaAdipo ECM, and ZAG peptide (pending clinical trials).
Products & technology
- MegaDermAcellular dermal matrix for breast reconstruction after cancer treatment
- MegaDerm SoftSubstitute for defective human skin
- MegaFill Hi-jectArthritis, disc, and fasciitis of the spine, shoulder, neck, and cartilage
- MegaNerve PrimeReplacement for damaged peripheral nerves (peripheral neuropathy, nerve loss)
- ES.FillSubstitute for defective human skin and skin regeneration
- MegaDBM SOrthopedic and dental implant material replacing bone loss from trauma or osteoporosis
- MegaCureBioabsorbable wound dressing for trauma and chronic open wounds
- MegaShieldAnti-adhesion barrier reducing adhesion after thyroid surgery
- MegaCartiCollagen-based tissue filler for focal knee cartilage defects and degenerative arthritis
- Mega Cartilage-ETissue-repair biomaterial for rhinoplasty
- MegaCare WNon-absorbable wound dressing for burns, skin graft sites, and foot ulcers
Regulatory approvals
data.go.kr126 Korean MFDS drug approvals · 2008–2024 / 23 Korean MFDS device approvals · 2011–2023
- MFDS drugMegatantan tablet 20mg2024-07-30Drug · Prescription · Approval202401842
- MFDS drugMegatantan tablet 5mg2024-07-30Drug · Prescription · Approval202401843
- MFDS drugMega Rosutin Tab. 2.5mg2024-06-13Drug · Prescription · Approval202401442
- MFDSTissue supplement, collagen2023-12-05Product approval · Class 4제허 23-1109 호
- MFDS drugacepherin Tab2022-12-09Drug · OTC · Notification202204455
- MFDSTissue supplement, collagen2022-11-15Product approval · Class 4제허 22-760 호
- MFDSGraft/prosthesis, biomaterial2022-06-07Product approval · Class 4제허 22-368 호
- MFDS drugFloxetine capsule (Fluoxetine hydrochloride)2022-01-11Drug · Prescription · Approval202200244
- MFDS drugDabiu Tab2021-12-29Drug · OTC · Notification202108189
- MFDSGraft/prosthesis, biomaterial2021-12-28Product approval · Class 4제허 21-1044 호
- MFDS drugMupicin Ointment(Mupirocin)2021-10-20Drug · OTC · Notification202107041
- MFDS drugVeni-F Tab2021-09-24Drug · OTC · Notification202106639
Show 68 more
- MFDS drugMomentasol Cream(Mometasone Furoate)2021-09-10Drug · Prescription · Notification202106493
- MFDSDressing, non-absorbable, wound, biological synthetic2021-06-24Product approval · Class 4제허 21-519 호
- MFDSDressing, adhesion barrier2021-03-15Product approval · Class 3제허 21-189 호
- MFDS drugMegabromel TabletRevoked2021-02-23Drug · OTC · Notification202101789
- MFDS drugL&C Megapen Tab.2020-10-06Drug · OTC · Notification202006755
- MFDSDressing, absorbable, wound, biological origin2020-09-17Product approval · Class 4제허 20-819 호
- MFDSBone graft, human source2020-07-15Product approval · Class 4제허 20-575 호
- MFDS drugMega Sarpo SR Tab. 300mg2020-05-21Drug · Prescription · Approval202003677
- MFDS drugEsome Tab. 20mg2020-05-21Drug · Prescription · Approval202003714
- MFDS drugMegatra Cap.2020-05-18Drug · Prescription · Approval202003621
- MFDS drugMega Solfena Tab. 5mg2020-05-15Drug · Prescription · Approval202003532
- MFDS drugMega Solfena Tab. 10mgRevoked2020-05-15Drug · Prescription · Approval202003533
- MFDS drugMegatelmichle Tab. 80/12.5mg2020-04-27Drug · Prescription · Approval202003085
- MFDS drugMega Acedol Semi Tab.2020-04-22Drug · Prescription · Approval202002850
- MFDS drugMega Acedol Tab.2020-04-16Drug · Prescription · Approval202002678
- MFDS drugMega Gli Tab. 4mgRevoked2020-04-13Drug · Prescription · Approval202002589
- MFDS drugrabenda Tab 10mg2020-04-06Drug · Prescription · Approval202002384
- MFDS drugrabenda Tab 20mg2020-04-06Drug · Prescription · Approval202002385
- MFDS drugOlmetan Tab. 40mg2020-03-31Drug · Prescription · Approval202002233
- MFDS drugOlmetan Tab. 10mg2020-03-31Drug · Prescription · Approval202002234
- MFDS drugMega Pio Tab. 15mg2020-03-27Drug · Prescription · Approval202002149
- MFDS drugMega Katihub Tab.Revoked2020-03-26Drug · Prescription · Notification202002120
- MFDS drugMega Vartan Tab. 160mgRevoked2020-03-25Drug · Prescription · Approval202002082
- MFDS drugMega Palo Inj.Revoked2020-03-20Drug · Prescription · Approval202001990
- MFDS drugMega Gli Tab. 2mgRevoked2020-03-19Drug · Prescription · Approval202001916
- MFDS drugMega Octylo Tab. 40mgRevoked2020-03-19Drug · Prescription · Approval202001923
- MFDS drugMegaclofenac Tab.2020-03-18Drug · Prescription · Approval202001890
- MFDS drugTamsurosin SR Tab. 0.2mg(Tamsulosin Hydrochloride)2020-03-17Drug · Prescription · Approval202001874
- MFDS drugMega Pivatin Tab. 2mgRevoked2020-03-17Drug · Prescription · Approval202001859
- MFDS drugMega Duta Soft Cap. 0.5mgRevoked2020-03-16Drug · Prescription · Approval202001802
- MFDS drugMega Vartan Tab. 80mg2020-03-10Drug · Prescription · Approval202001651
- MFDS drugMega Oflox Tab.Revoked2020-03-10Drug · Prescription · Approval202001652
- MFDS drugMega Alend Tab.Revoked2020-03-10Drug · Prescription · Approval202001654
- MFDS drugMega Coxib Cap. 200mg2020-03-06Drug · Prescription · Approval202001572
- MFDS drugMegatelmichle Tab. 40/12.5mg2020-03-04Drug · Prescription · Approval202001518
- MFDS drugMega Fudine Tab.Revoked2020-03-04Drug · Prescription · Approval202001514
- MFDS drugMega Diace Cap. 50mgRevoked2020-02-28Drug · Prescription · Approval202001423
- MFDS drugMega Prega Cap. 75mg2020-02-27Drug · Prescription · Approval202001371
- MFDS drugMega Prega Cap. 150mg2020-02-27Drug · Prescription · Approval202001372
- MFDS drugMega Fesia Tab. 5mg2020-02-25Drug · Prescription · Approval202001337
- MFDS drugMega Acedol Semi SR Tab.Revoked2020-02-24Drug · Prescription · Approval202001289
- MFDS drugMega Acedol SR Tab.Revoked2020-02-24Drug · Prescription · Approval202001290
- MFDS drugEsome Tab. 40mg2020-02-21Drug · Prescription · Approval202001244
- MFDS drugMega Febuk Tab. 40mgRevoked2020-02-21Drug · Prescription · Approval202001263
- MFDS drugMega Amlopine Tab.Revoked2020-02-20Drug · Prescription · Approval202001202
- MFDS drugMega Febuk Tab. 80mgRevoked2020-02-20Drug · Prescription · Approval202001229
- MFDS drugMega Mipide Tab.2020-02-18Drug · Prescription · Approval202001113
- MFDS drugMega Sarpo Tab. 100mg2020-02-18Drug · Prescription · Approval202001115
- MFDS drugMega Coxib Cap. 100mg2020-02-17Drug · Prescription · Approval202001044
- MFDS drugMega Simvatin Tab.Revoked2020-02-17Drug · Prescription · Approval202001045
- MFDS drugMega Tra Tab.Revoked2020-02-17Drug · Prescription · Approval202001047
- MFDS drugMega Rosatanchle TabRevoked2020-02-17Drug · Prescription · Approval202001070
- MFDS drugMega Loxicam Cap. 7.5mg2020-02-13Drug · Prescription · Approval202000927
- MFDS drugMega Loxicam Cap. 15mgRevoked2020-02-13Drug · Prescription · Approval202000928
- MFDS drugMega Batin Cap. 300mg2020-02-11Drug · Prescription · Approval202000804
- MFDS drugMega Batin Cap. 100mg2020-02-11Drug · Prescription · Approval202000805
- MFDS drugMega Cilozol Tab.Revoked2020-02-11Drug · Prescription · Approval202000814
- MFDS drugMega Simvae Tab. 10/10mgRevoked2020-02-10Drug · Prescription · Approval202000774
- MFDS drugMega Lesulpi Tab.2020-02-07Drug · Prescription · Approval202000716
- MFDS drugMega Rosutin Tab. 5mg2020-02-06Drug · Prescription · Approval202000698
- MFDS drugMega Famo Tab. 20mg2020-02-04Drug · Prescription · Approval202000592
- MFDS drugMega Omezole Cap. 20mgRevoked2020-02-04Drug · Prescription · Approval202000587
- MFDS drugMega Glimet Tab. 1/250mgRevoked2020-02-04Drug · Prescription · Approval202000589
- MFDS drugMega Glimet Tab. 2/500mgRevoked2020-02-04Drug · Prescription · Approval202000590
- MFDS drugMega Ezeti Tab. 10mgRevoked2020-02-04Drug · Prescription · Approval202000591
- MFDS drugMega Telmi Tab. 80mg2020-01-28Drug · Prescription · Approval202000419
- MFDS drugMega Telmi Tab. 40mg2020-01-28Drug · Prescription · Approval202000420
- MFDS drugMega Losatan Tab.2020-01-21Drug · Prescription · Approval202000343
Showing the 80 most recent of 149 records.
Clinical trials
data.go.kr9 MFDS clinical trial authorisations · 2022–2026 (Bioequivalence 9)
- BioequivalenceLNC26012026-04-01
1 trial site
- Bioequivalence메가프리드정(모사프리드시트르산염수화물)2022-08-08
1 trial site
- Bioequivalence메가에스틴정2022-04-11
1 trial site
- Bioequivalence메가터빈정2022-03-25
1 trial site
- Bioequivalence메가플나졸캡슐2022-03-17
1 trial site
- Bioequivalence메가클로피정75밀리그램2022-02-25
1 trial site
- Bioequivalence메가로수틴정20밀리그램2022-02-16
1 trial site
- Bioequivalence메가팜시버정(팜시클로비르)2022-02-03
1 trial site
- Bioequivalence도네페진정10밀리그램2022-01-18
1 trial site
R&D and key agreements
Source: DART corporate disclosureMegaFill Putty · 유방 등 연조직 절제 후 조직재건 · 공정밸리데이션 예정(2023 연구시작, 대한민국) · In-house development by L&C BIO
TendonFill · 인체 건/인대 손상 · 공정밸리데이션 예정(2023 연구시작, 대한민국) · In-house development by L&C BIO
Sheet type MegaFill · 화상, 외상 등으로 인한 피부 결손 · 제형 개발중(2025 연구시작, 대한민국) · In-house development by L&C BIO
MegaDerm Soft FD type · 개두술 후 손상된 연조직 보강 · 제형 개발중(2025 연구시작, 대한민국) · In-house development by L&C BIO
포켓형 ADM · 유방재건술에서 보형물 삽입 시 연부조직 보강 및 지지 · 제형 개발중(2025 연구시작, 대한민국) · In-house development by L&C BIO
MegaPlug · 발치 후 치조골 결손부 이식 재생유도 · 공정밸리데이션 예정(2024 연구시작, 대한민국) · In-house development by L&C BIO
MegaAdipo ECM · 안면성형 및 바디필러 · 임상 예정(2018 연구시작, 대한민국) · Tissue-repair biomaterial, in-house development by L&C BIO
Mega3DEar · 소이증 환자 귀 재건 · 임상 예정(2019 연구시작, 대한민국) · Designated orphan medical device, in-house development by L&C BIO
ZAG peptide · 아토피 피부염 및 상처 흔적 관련 피부질환 · 임상 예정(2018 연구시작, 대한민국) · In-house development by L&C BIO
ES.Stat · 출혈 부위의 지혈 · 개발중(2023 연구시작, 대한민국) · Absorbable internal hemostatic product, in-house development by L&C ES
Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
KOSDAQ-listed holding company making medical devices and biologics including bone graft rhBMP2 and knee implant TKR.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.
Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.
Founded in 1997 and KOSDAQ-listed in 2015, CG MedTech makes orthopedic medical devices and also operates an electric energy business.
Founded in 2016 and listed on KOSDAQ in 2017, DENTIS manufactures dental implants, medical LED lighting, and dental 3D printers.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
Spinal implant device maker founded 2008, listed on KOSDAQ 2016; produces Cervical and Thoraco Lumbar Cage, Screw, and Plate products.
Manufactures spinal implants and metal 3D-printed patient-specific implants, exporting to over 25 countries.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
Founded in 2010 and KOSDAQ-listed in 2018, Sejong Medical manufactures laparoscopic surgical instruments.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition